ArticlePloS one2025
Quantitative MRI relaxometry in brain tumor needle biopsies: Multimodal comparison with tissue fluorescence, radiology, and neuropathology.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuantitative MRI (qMRI) relaxometry holds potential for brain tumor identification beyond contrast enhancement on conventional images. However, clinical implementation is limited by long acquisition times, changing conditions between imaging and surgery, and lack of correlation with standard techniques. PURPOSE: To extend a methodology for multimodal data analysis to relaxometry data. To integrate relaxometry into the burr hole needle biopsy procedure with optical guidance, setup a workflow for multimodal data processing and analysis, and apply the methodology in a clinical setting.
methodsMulti-dimensional multi-echo relaxometry data (2x6 min) was acquired in addition to the clinical imaging protocol. Relaxation rate and proton density maps, as well as their differences were calculated before (R1, R2) and after gadolinium contrast-agent administration (R1Gd, R2Gd). Radiological volumes of interest (VOIs: tumor, edema, white matter, and biopsy) were defined on clinical images. Rate distribution changes were analyzed on three levels: the biopsied volume, along the needle trajectory (4x4x4 mm3 volumes), and VOIs. Increased R1Gd and R2Gd were compared to indications from 5-aminolevulinic acid-induced fluorescence and detailed neuropathological evaluation.
resultsNeuropathological analysis confirmed seven glioblastoma, one lymphoma, and one non-tumorous diagnosis. Increased R1Gd was found in all biopsied volumes, although tumorous volumes presented larger R1Gd increase (3-9 times) compared to volumes dominated by necrotic or non-tumorous tissue. Along the trajectory, increased R1Gd and R2Gd were not tumor-specific, however, the greatest R1Gd shifts were found in or adjacent to radiologically defined tumorous tissue. Increased relaxation rates corresponded to 82% and 45% (R1Gd: φ = 0.35, R2Gd: φ = 0.27) of fluorescence peaks. In the radiological VOIs, increased R1Gd and R2Gd were found in tumorous tissue, a slight right shift in edematous tissue, and negligible changes in white matter.
conclusionCombined analysis suggests increased R1Gd together with fluorescence peaks as a marker for tumor tissue. The presented multimodal approach provides a workflow toward clinical translation of relaxometry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.